By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexo AB 

Box 303

Uppsala    SE-751 05  Sweden
Phone: 46-0-18-780-88-00 Fax: 46-0-18-780-88-88



Company News
Orexo AB (ORXOF) Divests Subsidiary Kibion 4/30/2015 10:50:32 AM
Orexo AB (ORXOF): New 24-Week Clinical Study Strengthens The Evidence Of The Therapeutic Value Of Zubsolv® For Maintenance Treatment Of Opioid Dependence 4/22/2015 2:33:55 PM
Orexo AB (ORXOF) To Present At 2015 Nordic Life Sciences Conference 4/22/2015 2:09:28 PM
Report from Orexo AB (ORXOF)’s Annual General Meeting, 15 April 2015 4/16/2015 1:16:08 PM
Orexo AB (ORXOF)’s Annual Report for 2014 Released 3/25/2015 10:48:56 AM
Notice of Annual General Meeting Of Orexo AB (ORXOF) 3/16/2015 10:50:59 AM
Orexo AB (ORXOF) Broadens ZUBSOLV Product Range and Announces Newly Listed Granted U.S. Patent 2/17/2015 2:18:48 PM
Galena Biopharma  (GALE) Announces Orexo AB (ORXOF)'s Filing Of A Patent Infringement Lawsuit Against Actavis (ACT) Concerning Abstral (Fentanyl) Sublingual Tablets In The U.S. 2/5/2015 7:52:43 AM
Orexo AB (ORXOF): Full Year Report January-December 2014 1/29/2015 11:46:38 AM
Orexo AB (ORXOF) Receives Paragraph IV Notice Letter Concerning Abstral® In The U.S. 1/15/2015 9:40:57 AM